Federation des caisses Desjardins du Quebec’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $876K | Buy |
15,311
+1,996
| +15% | +$109K | ﹤0.01% | 1149 |
|
|
2026
Q1 | $752K | Sell |
13,315
-1,822
| -12% | -$106K | ﹤0.01% | 1109 |
|
|
2025
Q4 | $900K | Sell |
15,137
-183
| -1% | -$9.96K | ﹤0.01% | 1031 |
|
|
2025
Q3 | $830K | Buy |
15,320
+6,860
| +81% | +$392K | ﹤0.01% | 1020 |
|
|
2025
Q2 | $465K | Sell |
8,460
-12,973
| -61% | -$764K | ﹤0.01% | 1056 |
|
|
2025
Q1 | $1.52M | Buy |
21,433
+6,960
| +48% | +$468K | 0.01% | 706 |
|
|
2024
Q4 | $951K | Buy |
14,473
+5,884
| +69% | +$394K | ﹤0.01% | 807 |
|
|
2024
Q3 | $604K | Buy |
8,589
+991
| +13% | +$82.8K | ﹤0.01% | 908 |
|
|
2024
Q2 | $626K | Buy |
7,598
+2,398
| +46% | +$200K | ﹤0.01% | 882 |
|
|
2024
Q1 | $458K | Buy |
5,200
+1,050
| +25% | +$94K | ﹤0.01% | 903 |
|
|
2023
Q4 | $400K | Sell |
4,150
-1,791
| -30% | -$158K | ﹤0.01% | 830 |
|
|
2023
Q3 | $526K | Sell |
5,941
-639
| -10% | -$56.9K | 0.01% | 740 |
|
|
2023
Q2 | $570K | Sell |
6,580
-669
| -9% | -$63K | 0.01% | 730 |
|
|
2023
Q1 | $705K | Buy |
7,249
+4,830
| +200% | +$501K | 0.01% | 679 |
|
|
2022
Q4 | $250K | Buy |
2,419
+300
| +14% | +$28.2K | ﹤0.01% | 967 |
|
|
2022
Q3 | $180K | Sell |
2,119
-188
| -8% | -$16.7K | ﹤0.01% | 1121 |
|
|
2022
Q2 | $191K | Sell |
2,307
-80
| -3% | -$6.37K | ﹤0.01% | 1130 |
|
|
2022
Q1 | $184K | Buy |
2,387
+200
| +9% | +$16.7K | ﹤0.01% | 1167 |
|
|
2021
Q4 | $193K | Hold |
2,187
| – | – | ﹤0.01% | 1164 |
|
|
2021
Q3 | $169K | Buy |
2,187
+1,537
| +236% | +$121K | ﹤0.01% | 1215 |
|
|
2021
Q2 | $54.2K | Sell |
650
-1,037
| -61% | -$82.2K | ﹤0.01% | 1585 |
|
|
2021
Q1 | $127K | Sell |
1,687
-50
| -3% | -$4.08K | ﹤0.01% | 1257 |
|
|
2020
Q4 | $152K | Buy |
1,737
+987
| +132% | +$78.3K | ﹤0.01% | 1144 |
|
|
2020
Q3 | $57.1K | Buy |
750
+400
| +114% | +$40.5K | ﹤0.01% | 1201 |
|
|
2020
Q2 | $43.2K | Hold |
350
| – | – | ﹤0.01% | 1251 |
|
|
2020
Q1 | $29.6K | Hold |
350
| – | – | ﹤0.01% | 1403 |
|
|
2019
Q4 | $29.6K | Hold |
350
| – | – | ﹤0.01% | 1643 |
|
|
2019
Q3 | $23.6K | Hold |
350
| – | – | ﹤0.01% | 1636 |
|
|
2019
Q2 | $30K | Hold |
350
| – | – | ﹤0.01% | 1611 |
|
|
2019
Q1 | $31.1K | Hold |
350
| – | – | ﹤0.01% | 1425 |
|
|
2018
Q4 | $29.8K | Hold |
350
| – | – | ﹤0.01% | 1401 |
|
|
2018
Q3 | $33.9K | Hold |
350
| – | – | ﹤0.01% | 1442 |
|
|
2018
Q2 | $33K | Hold |
350
| – | – | ﹤0.01% | 1445 |
|
|
2018
Q1 | $28.4K | Buy |
+350
| New | +$30K | ﹤0.01% | 1480 |
|
|
2017
Q4 | – | Sell |
-100
| Closed | -$9.31K | – | 2136 |
|
|
2017
Q3 | $9.31K | Hold |
100
| – | – | ﹤0.01% | 1692 |
|
|
2017
Q2 | $9.08K | Hold |
100
| – | – | ﹤0.01% | 1760 |
|
|
2017
Q1 | $8.78K | Buy |
+100
| New | +$8.9K | ﹤0.01% | 1450 |
|
Other funds holding BMRN
Federation des caisses Desjardins du Quebec's BMRN Position: Q2 2026 in Review
Federation des caisses Desjardins du Quebec increased its BioMarin Pharmaceuticals (BMRN) stake by 15% in Q2 2026, buying an estimated $109K and bringing the position to 15,311 shares worth $876K. The position accounts for ﹤0.01% of the portfolio, ranked #1149.
Federation des caisses Desjardins du Quebec first reported a position in BMRN in Q1 2017 and has held it in 37 quarters since. The position peaked at $1.52M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Federation des caisses Desjardins du Quebec held 15,311 shares of BioMarin Pharmaceuticals worth $876K as of Q2 2026.
- Federation des caisses Desjardins du Quebec bought 1,996 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $109K.
- BioMarin Pharmaceuticals made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #1149 holding.
- Federation des caisses Desjardins du Quebec first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
- Federation des caisses Desjardins du Quebec's BioMarin Pharmaceuticals position peaked at $1.52M in Q1 2025.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.